Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 10

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 10
---
 0.05, because they may represent important therapeutic signals, and motivate
additional research.

<div align='center'>USE of PRODUCT VERSUS GENERIC NAMES</div>

This prospectus makes reference to two commercial
products owned/manufactured by 60P, Arakoda and Kodatef, which are approved by regulators in the United States and Australia, respectively,
for the prevention of malaria. The active molecule in those products is Tafenoquine succinate (Tafenoquine for short), which we are repositioning
for other indications using either (i) the same dosing regimen employed in the commercial Arakoda product (in which case reference is
made to the “Arakoda regimen of Tafenoquine” or (ii) different dosing regimens (in which case reference is made to “Tafenoquine”).
We also utilize the molecular name (Tafenoquine), where the active ingredient of Arakoda and Kodatef was tested in cell culture or animal
models. These different usages have been employed both for convenience and to avoid any assertions that Arakoda or Kodatef have been granted
marketing authorization by regulators for uses other than the prevention of malaria.

<div align='center'>MARKET DATA</div>

Market data and certain industry data and forecasts
used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available information,
reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys and forecasts
generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness
of such information is not guaranteed. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition,
we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements
regarding our market position are based on the most currently available data. While we are not aware of any misstatements regarding the
industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors,
including those discussed under the heading “Risk Factors” in this prospectus.

<div align='center'>iv</div>

PROSPECTUS SUMMARY Our Business We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a